CROI 2024 Program Guide

Interactive Symposia

Interactive Symposium-10 | Promise and Pitfalls of Biomedical Prevention: Beyond Phase III 4:00 PM - 5:30 PM • Four Seasons Ballroom 2-3 CME Objectives: At the completion of the session, participants will be able to: • List the challenges and opportunities in clinical implementation of long acting injectable cabotegravir • Describe reasons randomized phase III efficacy studies may not fully reflect the potential for benefit of an HIV prevention product • Identify and debunk common misconceptions about on-demand, event driven, or 2-1-1 preexposure prophylaxis (PrEP) Target Audience: This session is directed to clinicians, researchers, and others who are interested in biomedical HIV prevention Level of Knowledge: It is assumed that the participants are familiar with the phase III efficacy and safety trials of current HIV biomedical prevention products

Conveners Linda-Gail Bekker , Desmond Tutu HIV Foundation, Cape Town, South Africa Bruno Spire , Institut National de la Santé et de la Recherche Médicale, Marseille, France

48 | 4:00 PM | Why Is Cabotegravir Rollout So Slow? Rupa R. Patel , Centers for Disease Control and Prevention, Atlanta, GA, USA 49 | 4:20 PM | The Ring Comes Full Circle: Navigating the Complex Landscape of Biomedical Prevention Post-Phase III Leila E. Mansoor , Centre for the AIDS Programme of Research in South Africa, Durban, South Africa 50 | 4:40 PM | Challenging the Dogma of Event-Driven PrEP Jenell Stewart , Hennepin Healthcare Research Institute, Minneapolis, MN, USA

Wednesday

5:00 PM | Audience Questions and Answers

CROI 2024 65

New Investigator Scholarship

LB

NIS

Late-Breaking